Combo Immunotherapy With Durvalumab Effective for NSCLC
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 25, 2023 -- For patients with resectable non-small cell lung cancer (NSCLC), combination immunotherapy with the anti-programmed death-ligand 1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant setting, according to a study published online Sept. 14 in Cancer Discovery.
Tina Cascone, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues examined novel neoadjuvant immuno-oncology combinations for patients with resectable NSCLC using major pathological response (MPR) as the primary end point.
Eighty-three patients received a single cycle of treatment (26 durvalumab monotherapy, 21 durvalumab plus oleclumab [anti-CD73], 20 durvalumab plus monalizumab [anti-NKG2A], and 16 durvalumab plus danvatirsen [anti-STAT3 antisense oligonucleotide]). The researchers found that patients in the combination arms had higher MPR rates compared with those receiving durvalumab alone. The safety profiles were similar for the combinations and durvalumab alone. In the groups receiving durvalumab plus oleclumab and durvalumab plus monalizumab, improved MPR rates were associated with enhanced effector immune infiltration of tumors, interferon responses and markers of tertiary lymphoid structure formation, and systemic functional immune-cell activation.
"This study builds on the growing evidence that combination immunotherapy has a role in the neoadjuvant setting for this patient population," Cascone said in a statement. "Ultimately, we want to give patients a chance to live longer without their cancer returning."
Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which manufactures durvalumab and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Amivantamab-Lazertinib Ups Survival in EGFR-Mutated Advanced Lung Cancer
MONDAY, July 1, 2024 -- For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with...
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is Low
FRIDAY, June 21, 2024 -- The overall prevalence of up-to-date (UTD) lung cancer screening (LCS) was low in 2022, with prevalence increasing with age and number of comorbidities...
AI Blood-Based Lung Cancer Screening Test Developed for Fragmentome
MONDAY, June 10, 2024 -- A novel blood-based lung cancer screening test has been developed and validated using genome-wide sequencing to analyze cell-free DNA (cfDNA)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.